PapersPMID:24917198
A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression.
What moved
1 findingHow to read these marks →- Increases depression remission rate
very limited
“Depression remission rates were greater in the pregnenolone group (61%) compared with the placebo group (37%), as assessed by the IDS-SR (χ(2)(1)=3.99, p=0.046), but not the HRSD.”
- Study
- RCT
- Duration
- 3 months
- Dose studied
- pregnenolone titrated to 500 mg/day, add-on therapy
- Population
- Adults with bipolar disorder in a depressed mood state, pregnenolone or placebo added to ongoing therapy for 12 weeks; remission as assessed by the Inventory of Depressive Symptomatology-Self-Report (IDS-SR), not by the HRSD
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults with bipolar disorder, depressed mood state
- Participants
- 80
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 7